我院2007～2010年乳腺癌内分泌治疗药物的利用分析

Analysis on Application of Adjuvant Endocrine Therapeutic Drugs for Breast Cancer Patients in Our Hospital in 2007～2010

目的调查乳腺癌内分泌治疗药物的临床应用情况及使用趋势,评价用药合理性。方法 （1）分析山东大学附属省立医院2007~2010年乳腺癌内分泌治疗药物的销售金额、用药频率（DDD）及日用药金额（DDC）等指标。结果 （1）2007~2010年乳腺癌内分泌治疗药物临床用药金额平均增长率60%以上,其中第3代芳香化酶抑制剂增长最快;DDD由高至低排序依次为他莫昔芬、来曲唑、依西美坦、阿那曲唑、托瑞米芬;DDC由低至高依次为他莫昔芬、托瑞米芬、依西美坦、来曲唑、阿那曲唑。结论山东大学附属省立医院乳腺癌内分泌治疗药物使用量增长明显,用药趋势与指南推荐相符,表明内分泌治疗作为乳腺癌综合治疗手段之一日益得到临床重视,但在药物选择与使用时机上仍存在不合理之处。

Objective To investigate the clinical application status quo and tendency of adjuvant endocrine therapeutic drugs for breast cancer patients in our hospital, in order to evaluate the rationality of medication. Methods The consumption sum, defined daily dose （DDD）, daily drug cost （DDC） and other indicators of the endocrine therapeutic drugs for breast cancer patients in Provincial Hospital Affiliated to Shandong University were analyzed from 2007 to 2010. Results The average growth rate of total consumption sum of endocrine therapeutic drugs for breast cancer patients had been more than 60 % during the period of 2007-2010. Among them, the third-generation aromatase inhibitors grew the most rapidly. DDDs from high to low were tamoxifen, letrozole, exemestane, anastrozole, toremifene, and DDC from low to high were tamoxifen, toremifene, exemestane, letrozole, anastrozole. Conclusion The total use of endocrine therapeutic drugs for breast cancer increased greatly, which is consistent with the guidelines recommend. Endocrine therapy as one of the comprehensive treatments for breast cancer has held increasing clinical attention, but there is still something unreasonable existing in the drug selection and use ooportunitv.